Boston Scientific Corporation has announced that it received U.S. Food and Drug Administration (FDA) approval for expanded labeling of its FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system's use in pulmonary vein and posterior wall ablation for patients with persistent atrial fibrillation. This approval is backed by clinical evidence from the ADVANTAGE AF clinical trial, which demonstrated significant safety and effectiveness. The company plans further studies to expand its application in treating complex arrhythmias. Boston Scientific is also anticipating regulatory approvals in Europe, Japan, and China in the near future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。